{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:15:56Z","timestamp":1778670956127,"version":"3.51.4"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1097\/iae.0b013e3182721153","type":"journal-article","created":{"date-parts":[[2013,1,5]],"date-time":"2013-01-05T09:56:51Z","timestamp":1357379811000},"page":"748-755","source":"Crossref","is-referenced-by-count":10,"title":["INTRAVITREAL BEVACIZUMAB IN THE TREATMENT OF DIABETIC OCULAR NEOVASCULARIZATION"],"prefix":"10.1097","volume":"33","author":[{"given":"Osama H.","family":"Ababneh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yacoub A.","family":"Yousef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almutez M.","family":"Gharaibeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed A.","family":"Abu Ameerh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nakhleh E.","family":"Abu-Yaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muawyah D.","family":"Al Bdour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210130","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.survophthal.2006.10.017","article-title":"Ocular neovascularization: basic mechanisms and therapeutic advances.","volume":"52","author":"Dorrell","year":"2007","journal-title":"Surv Ophthalmol"},{"key":"R2-9-20210130","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/S0161-6420(84)34102-1","article-title":". The Wisconsin Epidemiologic Study of Diabetic Retinopathy, IV: diabetic macular edema.","volume":"91","author":"Klein","year":"1984","journal-title":"Ophthalmology"},{"key":"R3-9-20210130","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2174\/1389450054021981","article-title":". Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress.","volume":"6","author":"Caldwell","year":"2005","journal-title":"Curr Drug Targets"},{"key":"R4-9-20210130","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0002-9394(76)90292-0","article-title":"Preliminary report on effects of photocoagulation therapy.","volume":"81","year":"1976","journal-title":"Am J Ophthalmol"},{"key":"R5-9-20210130","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0161-6420(81)34978-1","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings: DRS Report number 8.","volume":"88","year":"1981","journal-title":"Ophthalmology"},{"key":"R6-9-20210130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00006982-199901000-00010","article-title":". Quantitative analysis of diabetic macular edema after scatter laser photocoagulation with the scanning retinal thickness analyzer.","volume":"19","author":"Tsujikawa","year":"1999","journal-title":"Retina"},{"issue":"suppl","key":"R7-9-20210130","first-page":"766","article-title":"Early photocoagulation for diabetic retinopathy. ETDRS report number 9.","volume":"98","year":"1991","journal-title":"Ophthalmology"},{"key":"R8-9-20210130","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.ophtha.2003.05.008","article-title":". Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision.","volume":"110","author":"Shimura","year":"2003","journal-title":"Ophthalmology"},{"key":"R9-9-20210130","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":". Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R10-9-20210130","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0161-6420(91)32085-2","article-title":". Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretinal photocoagulation.","volume":"98","author":"Vander","year":"1991","journal-title":"Ophthalmology"},{"key":"R11-9-20210130","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0161-6420(92)31779-8","article-title":". Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17.","volume":"99","author":"Flynn","year":"1992","journal-title":"Ophthalmology"},{"key":"R12-9-20210130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1023\/A:1009071601454","article-title":"Angiogenesis and ophthalmic disease.","volume":"3","author":"Adamis","year":"1999","journal-title":"Angiogenesis"},{"key":"R13-9-20210130","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress.","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocrinol Rev"},{"key":"R14-9-20210130","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00006982-200502000-00001","article-title":"The role of vascular endothelial growth factor in ocular health and disease.","volume":"25","author":"Adamis","year":"2005","journal-title":"Retina"},{"key":"R15-9-20210130","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0002-9394(01)01381-2","article-title":". Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate.","volume":"133","author":"Tolentino","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"R16-9-20210130","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/S0161-6420(96)30420-X","article-title":". Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate.","volume":"103","author":"Tolentino","year":"1996","journal-title":"Ophthalmology"},{"key":"R17-9-20210130","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","article-title":"Vascular permeability factorvascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.","volume":"20","author":"Dvorak","year":"2002","journal-title":"J Clin Oncol"},{"key":"R18-9-20210130","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/01.icu.0000143685.60479.3b","article-title":"Pharmacotherapy for diabetic retinopathy.","volume":"15","author":"Comer","year":"2004","journal-title":"Curr Opin Ophthalmol"},{"key":"R19-9-20210130","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":". Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer.","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"R20-9-20210130","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1517\/14712598.5.7.997","article-title":"Bevacizumab in the treatment of colorectal cancer.","volume":"5","author":"Mulcahy","year":"2005","journal-title":"Expert Opin Biol Ther"},{"key":"R21-9-20210130","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2005.10.017","article-title":". Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.","volume":"23","author":"Hurwitz","year":"2005","journal-title":"J Clin Oncol"},{"key":"R22-9-20210130","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":". Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R23-9-20210130","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","article-title":"Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"R24-9-20210130","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00006982-200603000-00016","article-title":"Regression of retina and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.","volume":"26","author":"Avery","year":"2006","journal-title":"Retina"},{"key":"R25-9-20210130","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ajo.2006.02.045","article-title":". Intracameral bevacizumab for iris rubeosis.","volume":"142","author":"Grisanti","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R26-9-20210130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ophtha.2005.10.012","article-title":"Changes in retinal neovascularization following pegaptanib (Macugen) therapy in diabetic individuals.","volume":"113","year":"2006","journal-title":"Ophthalmology"},{"key":"R27-9-20210130","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","article-title":". Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.","volume":"112","author":"Michels","year":"2005","journal-title":"Ophthalmology"},{"key":"R29-9-20210130","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1600-0420.2007.01042.x","article-title":". Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy.","volume":"86","author":"Minnella","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"R30-9-20210130","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/01.iae.0000246884.76018.63","article-title":". Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE STUDY).","volume":"26","author":"Jorge","year":"2006","journal-title":"Retina"},{"key":"R31-9-20210130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.eye.6702980","article-title":". Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up.","volume":"23","author":"Arevalo","year":"2009","journal-title":"Eye"},{"key":"R32-9-20210130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/157339909787314121","article-title":"Intravitreal bevacizumab for diabetic retinopathy.","volume":"5","author":"Arevalo","year":"2009","journal-title":"Curr Diabetes Rev"},{"key":"R33-9-20210130","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/IJG.0b013e3181997211","article-title":". Intravitreal bevacizumab for neovascular glaucoma, a randomized controlled trial.","volume":"18","author":"Yazdani","year":"2009","journal-title":"J Glaucoma"},{"key":"R34-9-20210130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1444-0938.2008.00295.x","article-title":"Rapid resolution of severe retinal neovascularization in proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab (Avastin).","volume":"92","author":"Thew","year":"2009","journal-title":"Clin Exp Optom"},{"key":"R35-9-20210130","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.ophtha.2004.03.035","article-title":"Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy.","volume":"111","author":"Itakura","year":"2004","journal-title":"Ophthalmology"},{"key":"R36-9-20210130","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ajo.2008.07.007","article-title":"Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents.","volume":"146","author":"Kim","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R37-9-20210130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","article-title":". Twelve month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan American Collaborative Retina Study Group (PACORES).","volume":"246","author":"Wu","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R38-9-20210130","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ajo.2006.02.015","article-title":"Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy.","volume":"142","author":"Oshima","year":"2006","journal-title":"Am J Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00006982-201304000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:30:06Z","timestamp":1618277406000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201304000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e3182721153","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}